Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.62 USD | -4.36% | +2.61% | -8.00% |
04-12 | Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing | MT |
04-04 | Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 51
Managers
Managers | Title | Age | Since |
---|---|---|---|
Benjamin Dake
FOU | Founder | 48 | 18-07-26 |
Timothy Noyes
CEO | Chief Executive Officer | 62 | 21-01-31 |
George Eldridge
DFI | Director of Finance/CFO | 61 | 21-02-28 |
Marco Verwijs
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
Hunter Gillies
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-04-30 |
Ralph Niven
CTO | Chief Tech/Sci/R&D Officer | 64 | 20-06-30 |
Timothy Pigot
PRN | Corporate Officer/Principal | - | 21-05-31 |
Sue Fischer
PRN | Corporate Officer/Principal | - | - |
Donna Dea
LAW | General Counsel | - | 20-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Donald Santel
BRD | Director/Board Member | 62 | 23-01-18 |
Maha Katabi
BRD | Director/Board Member | 50 | 20-07-31 |
Timothy Noyes
CEO | Chief Executive Officer | 62 | 21-01-31 |
Dave Grayzel
BRD | Director/Board Member | 56 | 20-07-31 |
Mark Iwicki
BRD | Director/Board Member | 57 | 21-01-31 |
Joshua Resnick
BRD | Director/Board Member | 49 | 18-09-30 |
Allison Dorval
BRD | Director/Board Member | 48 | 21-07-14 |
Habib Dable
CHM | Chairman | 54 | 23-07-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 28,737,381 | 28,728,904 ( 99.97 %) | 0 | 99.97 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.00% | 620M | |
+22.63% | 47.02B | |
+49.39% | 41.86B | |
-0.16% | 41.76B | |
-4.27% | 28.8B | |
+12.35% | 26.05B | |
-21.62% | 19.15B | |
+3.97% | 12.55B | |
+29.75% | 12.34B | |
-4.23% | 11.82B |
- Stock Market
- Equities
- AVTE Stock
- Company Aerovate Therapeutics, Inc.